New Optical Windows Let Scientists Watch the Living Mouse Brain for Weeks

Peering through the skull into the living brain has long been a compromise between clarity and damage. Multiphoton microscopy has become one of neuroscience’s most powerful tools, allowing researchers to watch individual cells and their dynamic interactions deep inside the cortex of a living mouse, week after week. But the skull itself is a stubborn optical obstacle: opaque, turbid, and full of structures that scatter and distort light before it ever reaches a fluorescent cell. The standard solution, the open-skull cranial window, delivers superb images but at a cost — inflammation, glial activation, permanent changes in neural connectivity, and disruption of the cerebrospinal fluid that bathes the brain. A new study published in Advanced Science systematically compares the less invasive alternatives and, in doing so, uncovers the fundamental culprit that has quietly limited every transcranial window ever made: the skull grows back.

The research team, working at the Hong Kong University of Science and Technology, evaluated four transcranial approaches in transgenic mice whose microglia — the brain’s resident immune cells — glow with green fluorescent protein. The thinned-skull window removes only the outer bone layer, leaving a delicate membrane roughly 20 to 50 micrometers thick. The PoRTS window polishes and reinforces that thinned bone with transparent cyanoacrylate cement, extending the usable field of view to three by three millimeters. The optical clearing window leaves the skull intact and instead strips out lipids and collagens chemically while matching the bone’s refractive index, rendering it transparent. Finally, the team introduced a hybrid they call the thinned-clearing window, which thins the skull first and then applies the clearing agents, dramatically accelerating a process that can otherwise take more than an hour in older animals.

That hybrid design proved to be the standout performer. In aged mice, blood vessels become embedded in the spongy inner bone, and clearing an intact skull around them is slow and often incomplete. By thinning the outer layer first, the researchers cut clearing time from roughly an hour to about ten minutes and achieved a 1.7-fold boost in fluorescence signal compared with the thinned-skull window alone. High-resolution imaging depth also improved significantly, from roughly 120 to 150 micrometers under the other windows to about 200 micrometers under the thinned-clearing window — enough to resolve the finest branches of microglial processes that blur away under conventional optics.

To understand precisely why image quality collapses with depth, the team turned to adaptive optics. Using a wavefront-sensor-based system that measures optical distortion directly from fluorescent guide stars — individual microglia at depths of 50, 150, and 250 micrometers — they quantified wavefront errors across all window types. Surprisingly, the root-mean-square and peak-to-valley aberration metrics showed no significant differences between windows, even though the thinned-clearing window delivered brighter, deeper images. The likely explanation is that the extra improvement comes from reduced scattering, which wavefront sensors are relatively insensitive to. What the measurements did reveal is that aberrations climb steeply with depth, because the focused laser beam sweeps through a wider cone of bone deeper in the tissue, accumulating distortion along the way.

The team then deployed a state-of-the-art adaptive optics two-photon microscope, known as the ALPHA-FSS system, which senses the distorted light field directly from fluorescent cells and compensates for it using a spatial light modulator. Through a thinned-clearing window, this system resolved the finest microglial processes at depths beyond 440 micrometers — more than double the reach of standard two-photon imaging through the same window. The improvement was consistent across all four window types, underscoring that adaptive optics is becoming essential equipment for anyone hoping to image the cortex at cellular resolution through intact bone.

But the most consequential discovery came from simply watching the windows age. Over 21 days of longitudinal imaging, fluorescence signals decayed rapidly in every window type, and the decay coincided with a growing layer of bone appearing on the inner surface of the skull. Third-harmonic generation imaging confirmed the diagnosis: mature osteocytes were visible in the original bone, and newly formed osteocytes appeared beneath it, marking fresh woven bone growing from the endosteum — the inner bone surface that no surgical preparation touches. Because the outer periosteum is removed during window preparation, the regenerative machinery of the bone is unleashed from the inside, driven by pathways such as Wnt and BMP signaling released from the stressed dura mater. Even re-thinning or re-clearing the window failed to restore the original signal, because this immature woven bone has optical properties that resist the clearing chemistry.

Recognizing bone regrowth as the fundamental bottleneck, the researchers pursued a counterintuitive strategy: exploiting a notorious side effect of glucocorticoid hormones, which suppress bone formation by inhibiting osteoblasts and promoting bone resorption. Applying an off-the-shelf dexamethasone ointment directly to the thinned skull held regrowth at bay for over four weeks, keeping fluorescence signals stable while untreated windows degraded within a week. Hydrocortisone ointment produced a similar effect. Yet glucocorticoids are small molecules that penetrate the meninges and diffuse into brain tissue, and the team observed that the commercial ointments displaced microglia and altered their morphology in the superficial cortex — a reminder that the brain’s immune sentinels are exquisitely sensitive to pharmacological interference.

The solution was dose control. By delivering dexamethasone through a drug-loaded sponge at a concentration tenfold lower than the commercial ointment — 0.0135 percent — the researchers still suppressed skull regrowth for 28 days while leaving microglial morphology in the superficial cortex essentially unchanged, with more than 70 percent of cells remaining stationary at the surface and no significant displacement below 60 micrometers. The team then went further, replacing the sponge with a transparent hydrogel made of hyaluronic acid methacrylate, loaded with the same moderate dexamethasone dose and sealed under a coverslip. The hydrogel window maintained high optical transparency, inhibited skull thickening for more than four weeks, and — because the drug released slowly — produced no detectable changes in microglial shape or distribution. The main limitation is dehydration: the hydrogel shrinks within a few days and must be refreshed every three to four days, a problem the authors expect future anti-dehydration hydrogel formulations to solve.

The study also delivered a practical warning about sealing materials. When thinned-skull windows were sealed with silicone gel, a common choice in the field, the researchers observed a rapid influx of inflammatory myeloid cells into the dura within days, scattering light and destroying image quality. Windows sealed with a removable UV gel showed no such collapse, suggesting that inadequate sealing allows infection-driven inflammation that had previously been mistaken for an inherent limitation of the technique. For laboratories choosing among window designs, the message is that sealant choice can matter as much as surgical skill.

Together, the findings give the neuroscience community something it has lacked: a quantitative map of how long each transcranial window lasts, how deep it can see, and what actually degrades it over time. Skull regrowth, it turns out, is not a nuisance specific to one preparation but a universal response that accelerates after the first week and cannot be reversed by re-treating the window. Suppressing it with carefully dosed glucocorticoids, delivered through an optically transparent hydrogel, extends high-quality imaging from days to weeks — a window of time long enough to track disease progression, therapeutic effects, and the slow choreography of the brain’s immune cells in health and disease. The authors caution that no concentration of dexamethasone eliminated microglial effects entirely, and that future work should seek agents that silence bone regrowth while remaining confined to the skull. For now, the combination of the thinned-clearing window, adaptive optics, and drug-loaded hydrogels offers one of the clearest, longest-lasting views yet into the living brain.

Subject of Research: Optical transcranial windows for long-term multiphoton brain imaging in living mice, including skull regrowth suppression with glucocorticoid-loaded hydrogels

Article Title: Optical Windows for Transcranial Brain Imaging in Living Mice: Skull Thinning, Clearing, and Beyond

Article References: Fu, Y., Yan, G., She, Z., He, Y., Liu, K., & Qu, J. (2026). Optical Windows for Transcranial Brain Imaging in Living Mice: Skull Thinning, Clearing, and Beyond. Advanced Science, 13(52), Article e76237. https://doi.org/10.1002/advs.76237

Image Credits: AI Generated

DOI: 10.1002/advs.76237

Keywords: transcranial window, multiphoton microscopy, skull regrowth, optical clearing, adaptive optics, thinned-skull window, dexamethasone, hydrogel, microglia, in vivo brain imaging, two-photon fluorescence, wavefront aberration